Recombigain: A human recombinant amelogenin therapy for hard and soft tissue regeneration.

Regulatory Path: Registered as a Medical Device Class III in Israel. Same regulatory path for Europe (MDR 2017/745) and USA (21-CFR).

Novel technology: The protein is manufactured in a recombinant production process– no animal source ingredients.

Purity: A single active ingredient carefully crafted into a patented formulation.

Efficacy: A potent rAmelX enamel matrix amelogenin protein.

Non leak formula: A thermodynamic formulation – liquid in the refrigerator and a thick viscous mucoadhesive gel in body temperature. Transforms in seconds.

Reproducibility: A batch consistent production process with exactly 0.5mg/g rAmelX per syringe.

Cost effectiveness: One syringe per package and a one step application (no need for a pre-application gel).